In a postmenopausal woman with estrogen‑receptor‑positive early breast cancer, how should aromatase inhibitors be used to prevent recurrence?

Aromatase Inhibitors for Prevention of Breast Cancer Recurrence in Postmenopausal Women

Postmenopausal women with estrogen-receptor-positive early breast cancer should receive an aromatase inhibitor (AI) as the cornerstone of adjuvant endocrine therapy, either as initial therapy for 5 years, sequentially after 2-3 years of tamoxifen, or as extended therapy following 4.5-6 years of tamoxifen, with AIs demonstrating superior disease-free survival compared to tamoxifen alone. 1, 2

Primary Treatment Strategies

The NCCN guidelines explicitly recommend three evidence-based approaches for incorporating AIs into adjuvant therapy 1, 2:

• Initial adjuvant therapy: Start an AI immediately after surgery and continue for 5 years (Category 1 recommendation). This approach is preferred for newly diagnosed postmenopausal women. 2

• Sequential therapy: Begin with tamoxifen for 2-3 years, then switch to an AI to complete a total of 5 years of endocrine therapy. This strategy provides overall survival benefit (HR 0.53 for anastrozole sequential therapy; HR 0.83 for exemestane sequential therapy). 1, 3

• Extended therapy: After completing 4.5-6 years of tamoxifen, add letrozole for additional years. The MA-17 trial demonstrated survival advantage specifically in node-positive disease (HR 0.61; 95% CI 0.38-0.98; P=0.04). 1, 2

Evidence for Superior Efficacy

AIs consistently outperform tamoxifen monotherapy in reducing recurrence risk. The ATAC trial with 100 months follow-up demonstrated fewer recurrences with anastrozole versus tamoxifen (HR 0.85; 95% CI 0.76-0.94; P=0.003) in 5,216 postmenopausal women with hormone receptor-positive disease. 1

The BIG 1-98 trial showed letrozole superiority over tamoxifen for disease-free survival (HR 0.81; 95% CI 0.70-0.93; P=0.003). 2

A critical caveat: While disease-free survival consistently favors AIs, overall survival differences have not been demonstrated in most trials comparing initial AI therapy versus tamoxifen alone. 2 The survival benefit emerges primarily in sequential and extended therapy strategies, and specifically in node-positive patients. 1

Duration of Therapy

For standard-risk patients: 5 years of AI-containing therapy (either upfront or sequential) represents the evidence-based minimum. 1, 2, 4

For high-risk patients: The St. Gallen International Consensus recommends extending AI therapy to 7-8 years (up to 10 years) for stage II disease to maximize recurrence reduction and survival benefit. 2

Even incomplete AI therapy provides meaningful benefit: Sequential therapy trials demonstrate that 2-3 years of AI exposure after tamoxifen produces a recurrence-rate ratio of 0.56 (95% CI 0.46-0.67) during the treatment period, indicating substantial benefit even with limited AI duration. 4

Critical Contraindication

AIs are absolutely contraindicated in premenopausal women with functioning ovaries. 1, 2 For women who become amenorrheic with chemotherapy, serial assessment of luteinizing hormone, follicle-stimulating hormone, and estradiol is mandatory to confirm true postmenopausal status before initiating AI therapy. 2 AIs do not adequately suppress ovarian estrogen synthesis and are ineffective without confirmed ovarian suppression. 2

Comparative Safety Profile

AIs offer significant advantages over tamoxifen for serious adverse events 5:

• Lower endometrial cancer risk: 0.2% with anastrozole vs 0.8% with tamoxifen (P=0.02) 2, 5
• Reduced thromboembolic events: 2.8% vs 4.5% (P=0.0004) 2, 5
• Fewer cerebrovascular events: 2.0% vs 2.8% (P=0.03) 2, 5
• Less vaginal bleeding and discharge 2, 5

However, AIs have distinct disadvantages 1, 2, 5:

• Higher bone fracture rates: 11.0% with anastrozole vs 7.7% with tamoxifen (P<0.0001) 2, 5
• Increased arthralgias: 35.6% vs 29.4% (P<0.0001) 2, 5

Essential Monitoring Requirements

Baseline bone mineral density assessment via DEXA scan is required for all patients >65 years before starting AI therapy, with serial assessments every 1-2 years during treatment. 2, 5 Consider upfront bisphosphonate therapy (zoledronic acid 4 mg IV every 6 months or oral alternatives) to preserve bone density and potentially improve disease-free survival. 5

Selection Among Individual AIs

The NCCN panel finds no compelling evidence that anastrozole, letrozole, and exemestane have meaningful differences in efficacy. 2 However, anastrozole demonstrates the most favorable cardiovascular safety profile, with no significant increase in cardiovascular deaths compared to tamoxifen, whereas letrozole showed concerning cardiovascular signals in the BIG 1-98 trial. 5 This cardiovascular risk is NOT a class effect and varies between individual AIs. 5

Practical algorithm for AI selection:

• First-line choice: Anastrozole for 5 years, given superior overall tolerability and cardiovascular safety 5
• Alternative: Letrozole if anastrozole unavailable, with superior disease-free survival data 2, 5
• Sequential option: Exemestane after 2-3 years of tamoxifen, FDA-approved for this indication 3
• Patients with significant cardiovascular disease: Preferentially select anastrozole over letrozole 5

Common Pitfall to Avoid

Never combine tamoxifen with an AI simultaneously. The ATAC trial demonstrated that patients receiving combined tamoxifen and anastrozole gained no benefit over tamoxifen alone, suggesting a deleterious effect from tamoxifen's weak estrogenic activity in the setting of near-complete estrogen elimination by the AI. 1